retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Eli Lilly's retatrutide shows promising

Tracking intake matters more on GLP-1, not less

Ongoing long-term studies and cancer-specific registries are needed to provide more definitive answers about safety in breast cancer survivors specifically

Create Accountability Share your goals with a partner, coach, or community for motivation and consistency

Most patients find that GI side effects diminish within the first few weeks at each new dose level

Given its benefits for cardiovascular health, Semaglutide may be particularly beneficial for individuals with type 2 diabetes who are also at risk for cardiovascular events

3740 Potentially just as important, GLP-1 also acts as a -cell growth factor so that in mice, it stimulates -cell proliferation while also exerting a prosurvival (antiapoptosis) action to protect against -cell death